Los Angeles Capital Management & Equity Research Inc. lowered its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 29.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,351 shares of the medical research company’s stock after selling 2,285 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Thermo Fisher Scientific were worth $822,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. Independent Portfolio Consultants Inc. boosted its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the period. Washington Trust Bank boosted its stake in shares of Thermo Fisher Scientific by 0.5% in the first quarter. Washington Trust Bank now owns 2,210 shares of the medical research company’s stock worth $339,000 after buying an additional 10 shares during the period. Beacon Trust Co. boosted its stake in shares of Thermo Fisher Scientific by 0.6% in the first quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock worth $341,000 after buying an additional 12 shares during the period. Dumont & Blake Investment Advisors LLC boosted its position in Thermo Fisher Scientific by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 5,526 shares of the medical research company’s stock worth $849,000 after buying an additional 15 shares during the last quarter. Finally, Ipswich Investment Management Co. Inc. boosted its position in Thermo Fisher Scientific by 0.3% in the first quarter. Ipswich Investment Management Co. Inc. now owns 9,285 shares of the medical research company’s stock worth $1,426,000 after buying an additional 30 shares during the last quarter. Institutional investors and hedge funds own 87.15% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) traded down 1.89% during mid-day trading on Tuesday, hitting $173.99. The stock had a trading volume of 1,648,460 shares. The firm has a market capitalization of $67.86 billion, a price-to-earnings ratio of 30.31 and a beta of 1.06. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The stock’s 50-day moving average is $177.02 and its 200 day moving average is $164.40.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same period in the prior year, the firm posted $2.03 earnings per share. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.34%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/08/thermo-fisher-scientific-inc-nysetmo-shares-sold-by-los-angeles-capital-management-equity-research-inc-updated-updated-updated.html.

TMO has been the subject of a number of research analyst reports. Cantor Fitzgerald initiated coverage on Thermo Fisher Scientific in a research note on Thursday, May 18th. They issued an “overweight” rating and a $194.00 target price for the company. Barclays PLC set a $175.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 26th. Cowen and Company restated an “outperform” rating and issued a $185.00 price target (up from $175.00) on shares of Thermo Fisher Scientific in a report on Saturday, April 29th. Citigroup Inc. restated a “buy” rating and issued a $201.00 price target (up from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. Finally, BidaskClub upgraded Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and a consensus target price of $188.56.

In related news, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the transaction, the chief executive officer now owns 269,279 shares in the company, valued at $46,528,718.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel P. Shine sold 4,688 shares of the business’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total transaction of $805,773.44. Following the transaction, the insider now owns 29,200 shares in the company, valued at approximately $5,018,896. The disclosure for this sale can be found here. Insiders have sold 27,188 shares of company stock worth $4,702,223 in the last quarter. 0.49% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.